Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
978.45
-4.75 (-0.48%)
Jul 9, 2025, 3:29 PM IST
Zydus Lifesciences Revenue
In the fiscal year ending March 31, 2025, Zydus Lifesciences had annual revenue of 232.42B INR with 18.90% growth. Zydus Lifesciences had revenue of 65.28B in the quarter ending March 31, 2025, with 17.96% growth.
Revenue
232.42B
Revenue Growth
+18.90%
P/S Ratio
4.24
Revenue / Employee
8.63M
Employees
26,921
Market Cap
984.55B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 232.42B | 36.94B | 18.90% |
Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
Mar 31, 2021 | 144.04B | 1.50B | 1.06% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 525.78B |
Divi's Laboratories | 93.60B |
Cipla | 272.67B |
Apollo Hospitals Enterprise | 217.94B |
Mankind Pharma | 122.07B |
Aurobindo Pharma | 317.24B |
Fortis Healthcare | 77.83B |
Alkem Laboratories | 129.65B |
Zydus Lifesciences News
- 1 day ago - Jefferies maintains buy on Zydus Lifesciences, sees 15.5% upside on resilient FY26 growth outlook - Business Upturn
- 21 days ago - Zydus completes USFDA inspection at oncology plant with two minor observations, none related to data integrity - Business Upturn
- 27 days ago - Stocks to watch on June 12: Zydus Life, Adani Group, Tanla Platforms, HUL, Nazara Tech, MCX in focus - Business Upturn
- 4 weeks ago - Zydus receives USFDA EIR for Ankleshwar API facility with ‘No Action Indicated’ status - Business Upturn
- 4 weeks ago - Zydus receives EIR with VAI classification from USFDA for Dabhasa API facility - Business Upturn
- 4 weeks ago - Top stocks to buy today: Stock recommendations for June 5, 2025 - The Times of India
- 5 weeks ago - Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang - Benzinga
- 5 weeks ago - Zydus secures licensing rights for next-gen immuno-oncology platforms from US-based Agenus - Business Upturn